Clara N Curiel

Clara N Curiel

Director, Cutaneous Oncology Program
Division Chief, Dermatology
Member of the Graduate Faculty
Professor, BIO5 Institute
Professor, Medicine - (Tenure Track)
Primary Department
Department Affiliations
Contact
(520) 626-0307

Research Interest

Clara Curiel-Lewandroski, PhD, is the director of the Pigmented Lesion Clinic and Multidisciplinary Cutaneous Oncology Program, both part of the University of Arizona Cancer Center Skin Cancer Institute. She completed two research fellowships, the first in the Department of Dermatology at Harvard Medical School, and the second at the Ludwig Boltzman Institute and Immunobiology of the Skin at Miinster University in Germany. Dr. Curiel is certified by the American Board of Dermatology.Dr. Curiel-Lewandroski’s research focus is on melanoma chemoprevention, early detection of melanoma, cutaneous T cell lymphomas and skin cancer. She studied the extended use of non-steroidal anti-inflammatory drugs, particularly aspirin, and their ability to possibly decrease the risk of cutaneous medanoma (CM) development. CM is responsible for more than 77 percent of skin cancer deaths.

Publications

Rosales, A. M., Curiel, C. N., Pluchino, S., Tristano, S., & Sanchez de Leon, R. (1994). Effect of furosemide administration in the fluid filtration rate and pulmonary artery pressure in isolated rabbit lung. Act Cient Venez, 49, 18-26.
Curiel, C. N., Nijsten, T., & Kadin, M. (2004). Lymphomatoid papulosis in childhood: a retrospective cohort study of 35 cases. Arch Dermatol, 140(3), 306-12.
Nijsten, T., Curiel-Lewandrowski, C., & Kadin, M. E. (2004). Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases. Archives of dermatology, 140(3), 306-12.

Lymphomatoid papulosis (LyP) is a rare entity, considered to be part of the spectrum of the CD30(+) cutaneous lymphoproliferative disorders. About 10% to 20% of the adult LyP patients will develop an associated lymphoid malignancy. Only a few cases of LyP have been described in children, and the risk of associated lymphoid malignancies in these patients is not known.

Einspahr, J. G., Bowden, G. T., Alberts, D. S., McKenzie, N., Saboda, K., Warneke, J., Salasche, S., Ranger-Moore, J., Curiel-Lewandrowski, C., Nagle, R. B., Nickoloff, B. J., Brooks, C., Dong, Z., & Stratton, S. P. (2015). Cross-validation of murine UV signal transduction pathways in human skin. Photochemistry and photobiology, 84(2), 463-76.

Acute UVB irradiation of mouse skin results in activation of phospatidyinositol-3 (PI-3) kinase and mitogen-activated protein kinase (MAPK) pathways leading to altered protein phosphorylation and downstream transcription of genes. We determined whether activation of these pathways also occurs in human skin exposed to 4x minimal erythemic dose of UVB in 23 volunteers. Biopsies were taken prior to, at 30 min, 1 and 24 h post-UVB. In agreement with mouse studies, the earliest UV-induced changes in epidermis were seen in phospho-CREB (two- and five-fold at 30 min and 1 h) and in phospho-MAPKAPK-2 (three-fold at both 30 min and 1 h). At 1 h, phospho-c-JUN and phospho-p38 were increased five- and two-fold, respectively. Moreover, phospho-c-JUN and phospho-p38 were further increased at 24 h (12- and six-fold, respectively). Phospho-GSK-3beta was similarly increased at all time points. Increases in phospho-p53 (12-fold), COX-2 (four-fold), c-FOS (14-fold) and apoptosis were not seen until 24 h. Our data suggest that UVB acts through MAPK p38 and PI-3 kinase with phosphorylation of MAPKAPK-2, CREB, c-JUN, p38, GSK-3beta and p53 leading to marked increases in c-FOS, COX-2 and apoptosis. Validation of murine models in human skin will aid in development of effective skin cancer chemoprevention and prevention strategies.

Adams, A. E., Zwicker, J., Curiel, C. N., Kadin, M. E., & Falchuk, K. R. (2004). Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. J Am Acad Dermatol, 51(4), 660-2.